Sign In
Buy GRFS
$7.18
-0.100 (-1.37%)
At Close: Jun 23, 2026
Spanish court summons Gotham City founder in Grifols share price probe
08:15am, Thursday, 09'th Oct 2025
Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
Grifols: Significant Upside Likely Materializing
09:23pm, Thursday, 02'nd Oct 2025
Grifols demonstrates strong recovery, with leverage reduced to 4.2x and dividend reinstated, supporting a renewed investment case. GRFS posted robust Q2 2025 results: 7% revenue growth, 12.5% EBITDA g
GRFS or NBIX: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 24'th Sep 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those
Should Value Investors Buy Grifols (GRFS) Stock?
10:40am, Wednesday, 24'th Sep 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Should Value Investors Buy Grifols (GRFS) Stock?
06:01pm, Monday, 08'th Sep 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
All You Need to Know About Grifols (GRFS) Rating Upgrade to Buy
01:00pm, Thursday, 28'th Aug 2025
Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GRFS or NBIX: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 20'th Aug 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang f
Are Investors Undervaluing Grifols (GRFS) Right Now?
10:41am, Wednesday, 20'th Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
New Strong Sell Stocks for July 31st
06:46am, Thursday, 31'st Jul 2025
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
05:00am, Tuesday, 10'th Jun 2025
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development a
Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know
01:01pm, Thursday, 05'th Jun 2025
Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Grifols (GRFS) Stock Undervalued Right Now?
10:46am, Tuesday, 03'rd Jun 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
GRFS vs. STVN: Which Stock Is the Better Value Option?
12:46pm, Monday, 02'nd Jun 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang fo
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
04:05pm, Friday, 30'th May 2025
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company�
